Leukemia Clinical Trials in Ohio

Showing 1081-1100 of 1,856 trials

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00600015

This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens. Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice daily), or erlotinib (150 mg/day) and a placebo.

Non-Small Cell Lung Cancer

SCRI Development Innovations, LLC166 participantsStarted Feb 2008

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Marietta, Georgia, United States +13 more locations

COMPLETEDPhase 332 miles

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653

The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)

LymphomaAcute Lymphoblastic Leukemia

Bristol-Myers Squibb512 participantsStarted Oct 2015

Phoenix, Arizona, United States • Duarte, California, United States • Loma Linda, California, United States +93 more locations

PreviousPage 55 of 93Next

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Leukemia Trials in Other Cities

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

PEN-866 in Patients With Advanced Solid Malignancies

KRT-232 and TKI Study in Chronic Myeloid Leukemia

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Safety Study of MGA271 in Refractory Cancer

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Other Conditions in Ohio